This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.
Activity Details
584 * | Wed, 8/4/2010, 2:00 PM - 3:50 PM | CC-120 (West) |
Analysis of Composite Endpoints, Surrogate Endpoints, and Multicenter Trials — Contributed Papers | ||
Biopharmaceutical Section , ENAR | ||
Chair(s): Lihan Yan, FDA | ||
2:05 PM | Statistical and Clinical Characteristics of Composite Endpoint in Clinical Studies — Jeng Mah, Regulatory and Clinical Research Institute, Inc. | |
2:20 PM | Comparing the Performance of Composite Endpoints and Responder Definitions with a Unified Modeling Framework for Multiple Endpoints Within Clinical Trials — David Andrae, PPD, Inc. | |
2:35 PM | Total Migraine Freedom: A Potential Primary Endpoint to Assess Acute Treatment in Migraine — Anthony J. Rodgers, Merck & Co., Inc. | |
2:50 PM | A Nonparametric Test for the Validation of Surrogate Endpoints — Xiaopeng Miao, Boston University School of Public Health ; Yong-Cheng Wang, Biogen Idec ; Ashis Gangopadhyay, Boston University | |
3:05 PM | Statistical Challenges and Issues Related to Multiregion Trials — Sibabrata Banerjee, Merck & Co., Inc. ; Lucy Shneyer, Merck & Co., Inc. | |
3:20 PM | Expected Frequency of Allowed Forced Allocations in a Multicenter Clinical Trial — Suvajit Samanta, Merck Research Laboratories ; Olga Kuznetsova, Merck Research Laboratories | |
3:35 PM | Effect of Patient Allocation Schemes on the Power of a Test for Treatment Effect — Fanni Natanegara, Eli Lilly and Company ; Christel Faes, Hasselt University ; Geert Molenberghs, I-BioStat ; Craig Mallinckrodt, Eli Lilly and Company |
2010 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.